IM Cannabis (NASDAQ:IMCC – Get Free Report) and Alpha Cognition (NASDAQ:ACOG – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.
Risk & Volatility
IM Cannabis has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500.
Profitability
This table compares IM Cannabis and Alpha Cognition’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IM Cannabis | -39.62% | -585.96% | -58.32% |
| Alpha Cognition | -153.61% | -54.60% | -43.47% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IM Cannabis | $39.17 million | 0.01 | -$8.10 million | ($60.66) | -0.03 |
| Alpha Cognition | $10.22 million | 18.75 | -$20.67 million | ($1.10) | -8.00 |
IM Cannabis has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for IM Cannabis and Alpha Cognition, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
| Alpha Cognition | 0 | 0 | 5 | 0 | 3.00 |
Alpha Cognition has a consensus price target of $18.00, indicating a potential upside of 104.55%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than IM Cannabis.
Insider & Institutional Ownership
7.7% of IM Cannabis shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Alpha Cognition beats IM Cannabis on 9 of the 14 factors compared between the two stocks.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
